The causes of autoimmune diseases are complex. Stimulated by specific antigens, the immune system will be repeatedly or excessively activated, resulting in increased cytokine secretion, mediated immune response attacking normal tissues, or callus formation through compensatory pathways, thus impairing normal physiological functions.

Relying on our own antibody discovery and drug evaluation platform, we have developed highly-effective blocking antibodies for different types of autoimmune diseases to effectively reduce effector cell- and cytokine-mediated inflammatory responses, and then to influence the disease progress and to improve the quality of life in patients.

The treatment of malignant tumors has significantly developed  in recent years, especially the continuous breakthroughs in cancer immunotherapy. To further improve the clinical benefits for more patients and develop more effective treatment methods, we have cooperated with top domestic academic institutions and well-known companies in the industry to identify new targets, new mechanisms of action, and new combinations. At present, multiple molecules are in different stages of drug development.

Neurodegenerative diseases are a group of conditions characterized by the gradual atrophy and loss of specific neurons in the nervous system, resulting in chronic progressive pathological changes and functional impairments in corresponding structures. The main diseases in this category include Alzheimer's disease and Parkinson's disease. The pathogenesis of neurodegenerative diseases is not yet clear, and there are few therapeutic drugs available that can only alleviate symptoms and cannot reverse or prevent the loss of neurons. 

By leveraging of our proprietary platforms for discovery and evaluation of antibody and nucleic acid drug, we are developing various drugs for different neurodegenerative diseases. Among them, our independently developed antibody drug for Alzheimer's disease features in long half-life, low immunogenicity, and good clearance activity, which is expected to provide safer and more effective medication for patients with Alzheimer's disease.